Supplemental Online Content

McDermott JH, Mahaveer A, James RA, et al; PALOH Study Team. Rapid point-of-care genotyping to avoid aminoglycoside-induced ototoxicity in neonatal intensive care. *JAMA Pediatr.* Published online March 21, 2022. doi:10.1001/jamapediatrics.2022.0187

eFigure 1. Melt Curve Analysis
eFigure 2. Peak Height Assessment
eAppendix.
eTable 1. Interfering substances
eTable 2. Cross Reactivity
eTable 3. Pre-clinical Assay Validation Case Control Study Participants
eTable 4. Trial Management Committee: Monthly Meetings
eTable 5. Steering Committee: 6 Monthly Meetings
eTable 6. Stakeholders Committee

This supplemental material has been provided by the authors to give readers additional information about their work.
eAppendix.

1. Assay Background and Development

1.1. Background

The Genedrive® MT-RNR1 ID Kit was developed for use as In vitro diagnostic (IVD) molecular assay for the detection of the single nucleotide polymorphism (SNP) m.1555A>G affecting the mitochondrial gene MT-RNR1 in human buccal cells. The Genedrive® platform is a portable, rapid thermocycling, point of care test (POCT) instrument which we programmed to perform loop-mediated isothermal amplification (LAMP) nucleic acid amplification followed by end-point fluorescent hybridisation probe-based melt analysis detection to enable allelic discrimination.

The CE-IVD assay was designed to amplify the m.1555A>G region from a buccal swab sample suspended in a buffer solution, following reconstitution of lyophilised assay reagents contained in a sample cartridge (2-30°C storage), and LAMP before genotyping wild type (WT) and mutant (VAR) alleles by automated discrimination of the respective allele hybridisation probe melt temperature (Tm) position (eFigure 1). Sample analysis is automated without any user interpretation, providing the user with a simple “detected” or “not detected” actionable result in 26 mins of initiating sample analysis (~30 mins from sample collection to actionable result). The IFU and instructional video is available at https://www.genedrive.com/assays/rnr1-product.php).

Each individual Genedrive MT-RNR1 ID Kit contains all the reagents and accessories required for the detection of (SNP) m.1555A>G affecting the mitochondrial gene MT-RNR1 in human buccal cells. The Genedrive MT-RNR1 ID Kit is designed for use in conjunction with the Genedrive instrument and an android smartphone device running the Genedrive Connect application (in an integrated device version for commercial roll out). The Genedrive MT-RNR1 ID Kit contains a buccal swab and sample collection tube containing lysis buffer for the collection of buccal cells.

The Genedrive assay cartridge contains all the reagents needed to perform amplification and detection, in a lyophilised format. The lyophilised reagents are reconstituted with the lysis buffer using the Minivette. The cartridge is then closed and inserted into the Genedrive instrument, where the required metadata is inputted via the Genedrive Connect Application, prior to initiating the test. The test consists of a target DNA amplification step and an end-point melt curve analysis. The data is interpreted by the instrument software which displays the result interpretation clearly on the screen.
Genedrive MT-RNR1 ID Kit should be stored between 2°C to 30°C. The expiry date for each Genedrive MT-RNR1 ID Kit is identified on the kit label. Expired kits must not be used. Once the Genedrive assay cartridge has been removed from the mylar pouch and the strip cap has been removed it is stable up to 40°C for 3 hours.

1.2 Assay Inclusivity

Using a panel of 92 genomic DNA samples (Public Health England, Ethnic Diversity panel EDP-1, Catalogue No: 07020701) representing a number of ethnic backgrounds including: African, Oriental, Australian Aborigine, Thai, Italian, French, South American Indian, Japanese and Ashkenazi Jewish, the MT-RNR1 assay was shown to have 100% inclusivity across all ethnicities.

1.3 Analytical sensitivity

The analytical sensitivity, or Limit of detection (LoD), is defined as the lowest concentration which >95% of the tested samples generate a positive result and was determined to be 16 cells.

Whilst the clinical significance of reported heteroplasmy is unclear, the Genedrive MT-RNR1 ID Kit can detect the variant allele (m.1555G) at a level of 10% in a background of non-variant (m.1555A), with 100% detection rate.

1.4 Interfering substances

The effect of potentially interfering substances on the Genedrive MT-RNR1 ID Kit was evaluated using 18 potentially interfering substances spiked into adult and neonatal/infant buccal samples of non-variant (1555A) at a level predicted to be above the concentration likely to be found in a buccal sample. The substances tested are shown in eTable 1.

| Substance     | Concentration | Expected | Actual | Expected | Actual |
|---------------|---------------|----------|--------|----------|--------|
| Lysozyme      | 54.1 mg/L     | 8        | 8      | 8        | 8      |
| Lactoferrin   | 29 mg/L       | 8        | 8      | 8        | 8      |
| Glucose       | 14.7 μmol/L   | 8        | 8      | 8        | 8      |
| Urea          | 29.3 mmol/L   | 8        | 8      | 8        | 8      |
| Ammonia       | 329 mmol/L    | 8        | 8      | 8        | 8      |
| Mucin         | 2270 mg/L     | 8        | 8      | 8        | 8      |
| Albumin       | 149.2 mg/L    | 8        | 8      | 8        | 8      |
| Lactate       | 0.79 mmol/L   | 8        | 8      | 8        | 8      |
| α amylase     | 897 U         | 8        | 8      | 8        | 8      |
| Amino acids   | 1560 μmol/L   | 8        | 8      | 8        | 8      |
| IgA           | 156.5 mg/L    | 8        | 8      | 8        | 8      |

© 2022 McDermott JH et al. JAMA Pediatrics.
Whole blood | 0.90% | 4 | 4 | 4 | 4
Amniotic fluid | 3.60% | na | na | 4 | 4
Meconium | 10 mg/mL | na | na | 4 | 4
Breast milk | 1.80% | na | na | 4 | 4
Orange juice | 0.90% | 4 | 4 | na | na
Apple juice | 3.60% | 4 | 4 | na | na
Natural yoghurt | 10 mg/mL | 4 | 4 | na | na

**eTable 1. Interfering substances**

1.5 Exclusivity (Cross reactivity)

The effect of potential cross reactive commensal organisms was evaluated on the Genedrive MT-RNR1 ID Kit using gut, oral, skin and vaginal microbiome genomic DNA pools (ATCC MSA-1006, MSA-1004, MSA-1005, MSA-1007 respectively). 100% exclusivity was observed with $10^5$ genome copies/strain of all the organisms listed in eTable 2. False positive reactivity was observed with $10^6$ genome copies/strain using the gut microbiome sample pool in 3/7 replicate tests. However, since these false positive peaks were observed in the WT position there is no impact on the result of the MT-RNR1 test. No interference of expected test result was observed when challenging the assay at 3X LoD with $10^6$ genome copies/strain of each pool.

| Sample Pool | Strain | Cross Reactivity | Interference |
|-------------|--------|------------------|--------------|
| Gut Microbiome | Bacteroides fragilis (ATCC 25285D-5) | No reactivity | No Interference |
| | Bacteroides vulgatus (ATCC 8482D-5) | | |
| | Blidobacterium adolescentis (ATCC 15703D-5) | | |
| | Clostridoides difficile (ATCC 9689D-5) | | |
| | Enterococcus faecalis (ATCC 700802D-5) | | |
| | Lactobacillus plantarum (ATCC BAA-793D-5) | | |
| | Enterobacter cloacae (ATCC 13047D-5) | | |
| | Escherichia coli (ATCC 700926D-5) | | |
| | Helicobacter pylori (ATCC 700392D-5) | | |
| | Salmonella enterica subsp. enterica (ATCC9150D-5) | | |
| | Yerinia enterocolitica (ATCC 27729D-5) | | |
### Oral Microbiome

- *Fusobacterium nucleatum subsp. nucleatum* (ATCC 25586D-5)
- *Actinomyces odontolyticus* (ATCC 17982D-5)
- *Prevotella melaninogenica* (ATCC 25845D-5)
- *Fusobacterium nucleatum subsp. nucleatum* (ATCC 25586D-5)
- *Streptococcus mitis* (ATCC 49456D-5)
- *Veillonella parvula* (ATCC 17745D-5)
- *Haemophilus parainfluenzae* (ATCC 33392D-5)

| Microbiome | Microorganism | Reactivity | Interference |
|------------|---------------|------------|--------------|
| Oral       | No reactivity | No reactivity | No Interference |

### Vaginal Microbiome

- *Gardnerella vaginalis* (ATCC 14019D-5)
- *Lactobacillus gasseri* (ATCC 33323D-5)
- *Mycoplasma hominis* (ATCC 23114D-5)
- *Prevotella bivia* (ATCC 29303D-5)
- *Streptococcus agalactiae* (ATCC BAA-611D-5)
- *Lactobacillus jensenii* (ATCC 25258D-5)

| Microbiome | Microorganism | Reactivity | Interference |
|------------|---------------|------------|--------------|
| Vaginal    | No reactivity | No reactivity | No Interference |

### Skin Microbiome

- *Acinetobacter johnsonii* (ATCC 17909D-5)
- *Corynebacterium striatum* (ATCC 6940D-5)
- *Micrococcus luteus* (ATCC 4698D-5)
- *Cutibacterium acnes* (ATCC 11828D-5)
- *Staphylococcus epidermidis* (ATCC 12228D-5)
- *Streptococcus mitis* (ATCC 49456D-5)

| Microbiome | Microorganism | Reactivity | Interference |
|------------|---------------|------------|--------------|
| Skin       | No reactivity | No reactivity | No Interference |

---

**eTable 2. Cross Reactivity**

### 1.6 Diagnostic sensitivity and specificity

Prior to the implementation study, a case-control clinical performance study was conducted using prospectively collected and banked neonatal/infant and adult buccal samples. Due to the low prevalence of the m.1555A>G variant, a case-control design was chosen to allow for sufficient recruitment of cases to assess sensitivity of the test.

A total of 306 samples (sequenced) were available, with approximately one third of these representing neonatal buccal samples. Samples were prospectively collected. All 1555G variant samples were from adults. 10 samples returned “Test Failed” results on first test (3.27% test fail rate), which on retest reduced to 2 “Test Failed” results
(0.65% test fail rate), resulting in 304 samples from 159 donors included in diagnostic performance assessment (eTable 3).

- **Group 1 CONTROLS** – Individuals who are already known to not carry the m.1555A>G genetic variant, as previously tested on a blood sample through the normal clinical laboratory process. This group comprised seventy-four individual participants and 138 individual specimens.

- **Group 2 CASES** – Individuals who are already known to carry the m.1555A>G genetic variant as this will have previously been tested on a blood sample through the normal clinical laboratory process. These individuals collected buccal cells themselves remotely following instructions supplied. This group comprised thirty-two individual participants and sixty-two individual specimens.

- **Group 3 CONTROLS** – Children on the neonatal intensive care unit (NICU). These samples will be used to ensure there are no factors specific to neonatal swab sampling that would impair the assay. This group comprised fifty-five individual participants and 110 individual specimens.

In this case-control, the Genedrive MT-RNR1 ID Kit was validated for use in adult and neonatal populations to detect the MT.1555A>G SNP associated with aminoglycoside induced hearing loss. The sensitivity of the test is determined to be 100 % (95 % CI 93.9 to 100.0) and the specificity is determined to be 100 % (98.5 to 100.0), using sanger sequencing as the reference method.

| Group | Details | Number of Participants | Number of specimens |
|-------|---------|------------------------|---------------------|
| 1     | Adults with the MT-RNR1 A variant | 74 | 138 |
| 2     | Adults with the MT-RNR1 G variant | 32 | 60 |
| 3     | Neonates with the MT-RNR1 A variant | 53 | 106 |
|       | **Total** | **159** | **304** |

**eTable 3. Pre-clinical Assay Validation Case Control Study Participants**
2. Study Committee Membership

2.1 Trial Management Committee: Monthly Meetings

| Name                        | Institution                                                                 | Role                                                                 |
|------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Professor William Newman     | Manchester Centre for Genomic Medicine, Manchester                           | Consultant Clinical Geneticist & Professor of Translational Genomics |
| Dr John McDermott           | Manchester Centre for Genomic Medicine, Manchester                           | Clinical Research Fellow                                             |
| Professor Richard Body       | Emergency Department, Manchester Royal Infirmary, Manchester University NHS Foundation Trust | Consultant Emergency Medicine                                       |
| Professor Iain Bruce         | Paediatric ENT Department, Royal Manchester Children’s Hospital             | Consultant Paediatric Otolaryngologist & Professor of Paediatric Otolaryngology |
| Mr Peter Roberts             | Market Access & Reimbursement Solutions Ltd                                 | Value Analyst                                                        |
| Mr Duncan Stoddard           | DS Analytics, London, UK                                                     | Data Analyst                                                         |
| Ms Rachel Corry              | N/A                                                                          | Parent Representative                                               |
| Ms Julia Garlick             | N/A                                                                          | Parent Representative                                               |
| Dr Ajit Mahaveer             | Neonatal Intensive Care Unit, St Mary’s Hospital, Manchester                | Lead Consultant Neonatologist (St Mary’s)                           |
| Dr Nicola Booth              | Neonatal Intensive Care Unit, St Mary’s Hospital, Manchester                | Lead NICU Research Nurse (St Mary’s)                                |
| Professor Mark Turner        | Neonatal Intensive Care Unit, Liverpool Women’s Hospital                    | Lead Consultant Neonatologist (Liverpool Women’s)                    |
| Dr Gino Miele                | Genedrive Diagnostics Ltd, Manchester, UK                                    | R&D Director                                                        |
| Dr Sarah Barnett             | Genedrive Diagnostics Ltd, Manchester, UK                                    | Senior Product Manager                                               |
| Dr Rachel Mahood             | Manchester Centre for Genomic Medicine, Manchester                           | Project Manager                                                      |
| Dr Karen Tricker             | Manchester Centre for Genomic Medicine, Manchester                           | Project Manager                                                      |
| Dr Rhona Macleod             | Manchester Centre for Genomic Medicine, Manchester                           | PI for Staff Interview Study                                         |
| Dr Fiona Ulph                | Division of Psychology & Mental Health, University of Manchester             | PI for Parent Interview Study                                        |
| Mr Paul Wilson               | Alliance Manchester Business School, University of Manchester               | Implementation Scientist                                             |

2.2 Steering Committee: 6 Monthly Meetings

| Name                        | Institution                                    | Role                                                                 |
|------------------------------|-----------------------------------------------|----------------------------------------------------------------------|
| Professor Sir Munir Pirmohamed (Chair) | University of Liverpool                        | Professor of Pharmacology & Therapeutics                             |
| Professor Andrew Ewer        | University of Birmingham                      | Professor of Neonatal Medicine                                        |
| Dr Jonathan Sandoe           | University of Leeds                            | Associate Professor of Microbiology and Honorary Consultant Microbiologist |
| Dr Jane Theaker              | Kinomica Ltd                                   | Chief Executive Officer                                              |
| Professor Dyfrig Hughes      | Bangor University                              | Professor in Pharmacoeconomics                                       |
| Dr Lynne Webster             | Manchester University NHS Foundation Trust    | Head of Research & Development Office                                |

© 2022 McDermott JH et al. JAMA Pediatrics.
2.3 Stakeholders Committee

| Name                        | Institution                                               | Role                                  |
|-----------------------------|-----------------------------------------------------------|---------------------------------------|
| Vicki Kirwin (Chair)        | National Deaf Children’s Society                          | Development Manager                   |
| Professor Kevin Munro       | University of Manchester                                  | Professor of Audiology                |
| Ms Christine Ashworth       | Newborn Services MFT                                       | Directorate Manager                   |
| Ms Rachel Ward              | Manchester University NHS Foundation Trust                | Paediatric Audiologist                |
| Ms Lucy Culshaw             | Bliss (National Charity for babies born premature or sick)| Charity representative               |
| Ms Sonali Sanghvi           | Pharmacy Advisor                                           | Genomics Unit at NHS England          |
| Ms Lisa Juniper             | N/A                                                       | Parent Representative                 |
| Ms Laura Hawcroft           | N/A                                                       | Parent Representative                 |
| Mr Paul Wilson              | Alliance Manchester Business School, University of Manchester | Implementation Scientist              |

eTable 6. Stakeholders Committee

3. Inclusion & Exclusion Criteria

3.1 Inclusion criteria

All babies admitted to NICU across the two participating sites, commencing from the trial start date. This includes babies admitted directly from delivery suite, post-natal wards, midwifery led units or transferred from another neonatal unit. At the LWH site, babies who were screened for infection on the NICU but then transferred to external wards (not formally admitted to NICU) were also included. It is a clinical decision whether the babies are being screened for infection as part of their assessment, reflecting the real-world, pragmatic, nature of the trial. This also reflected the variation in admission procedures between the two trial sites where pathways differ due to local practices.

3.2 Exclusion Criteria

Babies requiring antibiotics immediately, as determined by the admitting clinician, with already established intravenous (IV) access. These exclusion criteria recognize the potential urgency of any decision to deliver antibiotics. If IV access has not been achieved, then this may provide time to run the assay. We expect that only a small proportion of admissions would be excluded based on these criteria.

4. MT-RNR1 Point of Care System Investigations

During the implementation phase there was “Test fail” rate of 17.4%, where genotyping failed, and five false positive events. The study design allowed genotyping data to be collected from the PALOH implementation trial to inform assay modification to improve the final system performance.

4.1 Failed Genotyping Investigations

© 2022 McDermott JH et al. JAMA Pediatrics.
The samples which had failed genotyping (“Test Fail”) during the PALOH trial were retrospectively reviewed. There was no association between failed genotyping and participant age, length of time between swab and testing, system, system user, assay batch or the time of day the test was performed. Subsequently, the melt peak data for those samples which had failed genotyping were retrospectively reviewed. A consistent feature of those samples which failed genotyping was a reduced signal intensity below acceptance threshold, meaning the peaks were not being identified by the system software and genotyping would fail. This appeared to be a root-cause of the increased “Test Fail” rate. Rather than lowering the threshold for a peak to be considered detected, which could reduce assay sensitivity, the assay buffer formulation was modified to improve analytical sensitivity, and subsequently lowered the assay LoD from 16 cells to 0.4 cells.

This version 2.0 (V2.0) chemistry was then tested on 35 patient samples which had all previously failed to generate a genotype (i.e. Test Fail) during the PALOH implementation trial. All samples irrevocably anonymised prior to repeated testing. The peak heights and outcome from each genotyping attempt was monitored. All samples were tested in a controlled laboratory setting and in the clinical setting, where the PALOH trial was performed.

Repeated testing of the 35 previously failed samples showed a significant improvement in the performance of the system, both in the laboratory and clinical settings. The average peak height was significantly increased using V2.0 of the MT-RNR1 assay (eFigure 2) which translated into a decreased Test Fail rate. In the laboratory setting, all of the previously failed samples were successfully genotyped (failure rate 0.0%) and in the clinical setting only 2 of 35 samples failed genotyping (failure rate 5.7%)

4.2 False Positive Event Investigations
Repeat testing of samples leading to false positive events ruled out sample contamination. False positive results were associated with irregular melting profile traces, with spikes and dips introduced into the fluorescent melt profile. Fluorescence spikes resulted in artefactual “peaks” passing subsequent quality metrics and fluorescent dips or dips resulted in possibility of masking true melt peaks, and therefore also potentially contributing to “test fail” results observed. These were determined to arise from incomplete assay cartridge insertion, resulted in vibrational derived artefacts and light ingress to the optical reader system during assay melt phase. The cartridge and cartridge inlet design were improved, with physical clip and auditory feedback to the user to ensure that these were inserted correctly. Following verification and confirmation of new design improvements, these were validated in the laboratory and intended user setting as above. Instructions for use (IFU) and a user video, demonstrating ideal use of the system including cartridge insertion, are available at https://www.genedrive.com/assays/rnr1-product.php.
4.3 Investigation Conclusion

Assay and instrument/assay cartridge design improvements have led to substantial improvement in assay analytical sensitivity, thereby addressing the “test fail” rate, and ensuring correct and complete cartridge assembly and insertion, thereby addressing potential false positive events derived from vibrational or light ingress related fluorescence artefacts. These post-implementation study identified design improvements have led through to commercially available CE marked product.

5. Supplementary (Online-Only) eFigures

5.1 eFigure 1

eFigure 1 Melt Curve Analysis. Differential peak heights between the m.1555A (WT) and the m.1555A>G (VAR) alleles, allowing reliable discrimination during genotyping.

5.2 eFigure 2

eFigure 2 Peak Height Assessment. Reformulation of the buffer chemistry for version 2.0 of the assay significantly increased the average peak height compared with version 1.0 of the assay. RFU= relative fluorescence units